Non-small Cell Carcinoma research hub
10 indexed studies · 3 currently recruiting
- recruitingPHASE3
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
This study compares a new medicine, PF-08046054, with a standard lung cancer treatment, Docetaxel. It's for adults with a certain type of lung cancer that has already been treated and has a specific marker called PD-L1.
United States · Argentina · Australia - active not recruitingPHASE2
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
This study looks at a new treatment called patritumab deruxtecan for people with an advanced type of lung cancer that has a specific genetic change (EGFR mutation). It's for those who have already tried other standard treatments that are no longer working.
United States · Australia · Austria - active not recruitingPHASE1, PHASE2
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
This study is testing a new cell therapy called gavo-cel for advanced cancers like mesothelioma and ovarian cancer. It explores how well gavo-cel works, both alone and with other cancer drugs, in people whose tumours produce a specific protein called mesothelin.
United States · Canada - recruiting
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
This study collects information from real-life lung cancer patients in Germany. It looks at how cancer is tested, treated, and how patients get on. The aim is to understand and improve care for lung cancer patients and see how different treatments affect them.
Germany - active not recruitingPHASE1, PHASE2
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
This study is looking into a new drug, MCLA-129, for some advanced cancers like lung or stomach cancer. It will see how safe and effective it is, both by itself and with other treatments. It's for people who haven't responded to previous treatments.
United States · Belgium · France - active not recruitingPHASE3
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
This study looks at a new treatment for advanced lung cancer in people aged 70-89. It combines standard chemotherapy (Carboplatin, Paclitaxel) with an immunotherapy drug called Atezolizumab, to see if it's effective and well-tolerated in this age group.
France - recruiting
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
This study looks at how well a treatment combining chemotherapy and amivantamab works for advanced lung cancer with specific gene changes. It helps us understand real-life results and safety for people already receiving this treatment through early access programs.
France - active not recruitingPHASE4
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
This study looks at new ways to treat advanced lung cancer that has spread. It compares two different drug combinations to see which works better for a specific type of lung cancer that doesn't have certain features.
Germany - active not recruitingPHASE2
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
This study is testing a new cancer medicine, acasunlimab, alone or with another drug, pembrolizumab, for a common type of lung cancer that has come back. It aims to see how safe and effective these treatments are.
United States · France · Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, open-label, Phase 3 study of SAR408701 versus docetaxel in previously treated, metastatic nonsquamous, non-small-cell lung cancer patients with CEACAM5-positive tumors
This study compares a new medicine (SAR408701) to a standard chemotherapy (docetaxel) for advanced non-small cell lung cancer. It aims to see if the new treatment helps people live longer and if their cancer is kept under control for longer.
France